Literature DB >> 6725514

Perivascular fibrosis in prolactinomas: is it increased by bromocriptine?

A M Landolt, V Osterwalder.   

Abstract

Prolonged treatment of patients with pituitary prolactinomas with bromocriptine may increase the consistency of the tumor thereby making selective extirpation more difficult. We made quantitative determinations of the amount of perivascular fibrous tissue in prolactinomas on random electron micrographs, comparing a group of 21 patients treated with bromocriptine for periods longer than 3 months and a control group of 21 patients who did not receive bromocriptine. Statistical analysis of the data showed a significant increase of perivascular fibrous tissue in the treated group (P less than 0.002). We suspect that this fibrosis is a consequence of the rapid shrinkage of prolactinoma cells caused by bromocriptine. Presumably, this cell shrinkage causes enlargement of the extracellular and perivascular spaces which are filled by the deposition of collagen, producing a more dense consistency of the adenoma.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6725514     DOI: 10.1210/jcem-58-6-1179

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  21 in total

Review 1.  Neurology of the pituitary gland.

Authors:  J R Anderson; N Antoun; N Burnet; K Chatterjee; O Edwards; J D Pickard; N Sarkies
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-06       Impact factor: 10.154

Review 2.  Medical management of prolactin-secreting pituitary adenomas.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

3.  Effect of dopaminergic drug treatment on surgical findings in prolactinomas.

Authors:  Maria Menucci; Alfredo Quiñones-Hinojosa; Peter Burger; Roberto Salvatori
Journal:  Pituitary       Date:  2011-03       Impact factor: 4.107

4.  Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization.

Authors:  K Kovacs; L Stefaneanu; E Horvath; R V Lloyd; I Lancranjan; M Buchfelder; R Fahlbusch
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

5.  Pituitary gland: can prolactinomas be cured medically?

Authors:  Mark E Molitch
Journal:  Nat Rev Endocrinol       Date:  2010-04       Impact factor: 43.330

6.  Magnetic resonance imaging of the normal pituitary gland using ultrashort TE (UTE) pulse sequences (REV 1.0).

Authors:  Olivia Portman; Stephen Flemming; Jeremy P D Cox; Desmond G Johnston; Graeme M Bydder
Journal:  Neuroradiology       Date:  2007-11-22       Impact factor: 2.804

7.  Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline.

Authors:  Giovanna Aparecida Balarini Lima; Evelyn de Oliveira Machado; Cintia Marques Dos Santos Silva; Paulo Niemeyer Filho; Mônica Roberto Gadelha
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

8.  3D-FT thin sections MRI of prolactin-secreting pituitary microadenomas.

Authors:  N Girard; T Brue; V Chabert-Orsini; C Raybaud; P Jaquet; M Poncet; F Grisoli; S Cahen
Journal:  Neuroradiology       Date:  1994-07       Impact factor: 2.804

9.  Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal.

Authors:  Margarida Teixeira; Pedro Souteiro; Davide Carvalho
Journal:  Pituitary       Date:  2017-08       Impact factor: 4.107

10.  Intratumoural cyst formation in pituitary macroadenomas.

Authors:  Z Ram; M Hadani; M Berezin; G Findler; A Sahar; I Shacked
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.